Dendritic cell therapy in melanoma
نویسندگان
چکیده
منابع مشابه
Optimizing Dendritic Cell Preparation for Fusion with Melanoma Cells
Background: Fusion of dendritic cells (DCs) with melanoma cells could reinforce the antigenicity of tumors as a strategy for the treatment of malignant melanoma. However, the insufficient quantity of DCs and the low fusion efficiency limits the development of such approach. Objective: To define the dosage of the stimulating factors as well as the induction condition for the optimal DCs prepara...
متن کاملA Model of Dendritic Cell Therapy for Melanoma
Dendritic cells are a promising immunotherapy tool for boosting an individual's antigen-specific immune response to cancer. We develop a mathematical model using differential and delay-differential equations to describe the interactions between dendritic cells, effector-immune cells, and tumor cells. We account for the trafficking of immune cells between lymph, blood, and tumor compartments. Ou...
متن کاملoptimizing dendritic cell preparation for fusion with melanoma cells
background: fusion of dendritic cells (dcs) with melanoma cells could reinforce the antigenicity of tumors as a strategy for the treatment of malignant melanoma. however, the insufficient quantity of dcs and the low fusion efficiency limits the development of such approach. objective: to define the dosage of the stimulating factors as well as the induction condition for the optimal dcs preparat...
متن کاملCancer Therapy: Clinical Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
Purpose: Tumor antigen–loaded dendritic cells (DC) are believed to activate antitumor immunity by stimulating T cells, and CTL-associated antigen 4 (CTLA4)–blocking antibodies should release a key negative regulatory pathway on T cells. The combination was tested in a phase I clinical trial in patients with advanced melanoma. Experimental Design: Autologous DC were pulsed with MART-126-35 pepti...
متن کاملAdjuvant dendritic cell vaccination in high-risk uveal melanoma patients
Background The presence of monosomy 3 in the primary tumor is widely accepted as the most reliable prognostic parameter, identified in approximately 50% of patients with primary uveal melanoma [1]. Long term studies have shown a 3-year survival rate of 40% if monosomy 3 is present, whereas tumors with normal chromosome 3 status rarely give rise to metastatic disease and have a 90% 3-year surviv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Translational Medicine
سال: 2017
ISSN: 2305-5839,2305-5847
DOI: 10.21037/atm.2017.06.13